Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Simultaneous Determination of Levetiracetam, Sodium Valproate, and Olanzapine in Human Plasma by UPLC-MS/MS for Therapeutic Drug Monitoring.

Biomedical chromatography : BMC·2026

Same author

[Characteristics of the Pathogenic Bacteria Isolated from the Lower Respiratory Tract of the Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2026

Same author

Identification of a novel major QTL and F-box candidate genes controlling seed dormancy in common wheat.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2026

Same author

Venetoclax plus Idarubicin and cytarabine as frontline induction for newly diagnosed acute myeloid leukemia in young, fit adults: a real-world study.

Annals of hematology·2026

Same author

Work engagement and associated factors of nurses: a structural equation model.

Frontiers in psychology·2026

Same author

Expedient Synthesis of Difficult Proteins via Fmoc Chemistry by Embedding 2-(2-Hydroxyphenyl)thiazolidine Dipeptides (HTDs) as Aggregation Disruptors.

The Journal of organic chemistry·2026

Same journal

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece.

Annals of hematology·2026

Same journal

Comparative thromboembolic risk of romiplostim versus eltrombopag in immune thrombocytopenia: a propensity score-matched cohort study.

Annals of hematology·2026

Same journal

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Annals of hematology·2026

Same journal

Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study.

Annals of hematology·2026

Same journal

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Annals of hematology·2026

Same journal

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

Annals of hematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 2, 2026

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Recent advances in CD5⁺ diffuse large B-cell lymphoma.

Ningning Yue¹, Qiqi Jin¹, Cuicui Li¹

¹Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China.

Annals of Hematology

|August 28, 2024

Summary

This summary is machine-generated.

CD5-positive Diffuse Large B-cell Lymphoma (DLBCL) is a rare, aggressive subtype of non-Hodgkin

Keywords:

CD5+ DLBCL High CNS relapse Novel therapy Poor prognosis

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Related Experiment Videos

Last Updated: May 2, 2026

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

Hematology
Oncology
Immunology

Background:

Diffuse Large B-cell Lymphoma (DLBCL) is the most common non-Hodgkin's Lymphoma (NHL).
CD5-positive (CD5+) DLBCL represents a rare and distinct subgroup, comprising 5-10% of DLBCL cases.
CD5+ DLBCL is associated with specific clinical and molecular features, including older age, female sex, elevated lactate dehydrogenase, poor ECOG performance status, advanced stage, and higher IPI scores.

Purpose of the Study:

To review the clinical characteristics, prognostic factors, and therapeutic strategies for CD5+ DLBCL.
To explore potential mechanisms contributing to the poor prognosis of CD5+ DLBCL.
To discuss emerging therapeutic options for CD5+ DLBCL.

Main Methods:

Literature review of studies on CD5+ DLBCL.
Analysis of clinical and molecular features of CD5+ DLBCL.
Evaluation of treatment outcomes and novel therapeutic approaches.

Main Results:

CD5+ DLBCL exhibits distinct molecular profiles, often expressing MYC, BCL-2, and MUM-1, and belonging to the ABC subtype.
Patients with CD5+ DLBCL frequently present with advanced disease, central nervous system relapse, and bone marrow involvement.
Standard R-CHOP chemotherapy shows limited efficacy in CD5+ DLBCL, necessitating alternative treatment strategies.

Conclusions:

CD5+ DLBCL is a heterogeneous and aggressive lymphoma subtype with unique clinical and biological characteristics.
The efficacy of R-CHOP is suboptimal, and the role of DA-EPOCH-R requires further investigation.
Novel therapies including BTK inhibitors, BCL-2 inhibitors, CXCR4 antagonists, and immunotherapy hold promise for improving outcomes in CD5+ DLBCL, warranting further clinical trials.